Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 13)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for CSII13$25  View Abstract
6-Feb-10Standard & Poor's Quantitative ReportN/ACardiovascular Systems5$25  View Abstract
5-Feb-10Ford Investor Services, Inc.N/AValue Graph: CARDIOVASCULAR -- CSII1$4  View Abstract
5-Feb-10Ford Investor Services, Inc.N/AIndustry Value Graph: ACAD , CSII , CERS , CRXX , GTXI , SGMO , UGNE -- DRUGS3$4  View Abstract
2-Feb-10EconomicInvestorN/A"The Economy Matters" Report for CSII: the economy's impact on CSII's price and risk, featuring the powerful EconomicInvestor Star Rating6$15  View Abstract
25-Jan-10Wall Street Transcript ,TheThe Wall St TranscriptANALYST INTERVIEW: Blurred Lines Between Life Sciences & Diagnostics - Stephen D. Simpson - Northland Securities, Inc.5$50  View Abstract
25-Jan-10Wall Street Transcript ,TheThe Wall St TranscriptWall Street Transcript Special Report: Medical Research, Diagnostic Substances, Life Science Tools Report35$150  View Abstract
19-Jan-10Zacks Investment Research Inc.N/ACARDIOVASCLR SY (CSII) Zacks Company Snapshot1$10  View Abstract
15-Jan-10Feltl & CompanyErnest W. AndbergCSII- FDA grants conditional approval for a clinical trial in calcified coronary arteries.6$254 Stars  View Abstract
4-Jan-10Zacks Investment Research Inc.N/ACARDIOVASCLR SY (CSII) Zacks Company Snapshot1$10  View Abstract
Next 3
Brokerage Reports (Showing 1 to 1 of 1)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
15-Jan-10Feltl & CompanyErnest W. AndbergCSII- FDA grants conditional approval for a clinical trial in calcified coronary arteries.6$254 Stars  View Abstract
Independent Reports (Showing 1 to 10 of 12)
Release
Date [down]		 Contributor Author Title Pages Price More Info
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for CSII13$25View Abstract
6-Feb-10Standard & Poor's Quantitative ReportN/ACardiovascular Systems5$25View Abstract
5-Feb-10Ford Investor Services, Inc.N/AValue Graph: CARDIOVASCULAR -- CSII1$4View Abstract
5-Feb-10Ford Investor Services, Inc.N/AIndustry Value Graph: ACAD , CSII , CERS , CRXX , GTXI , SGMO , UGNE -- DRUGS3$4View Abstract
2-Feb-10EconomicInvestorN/A"The Economy Matters" Report for CSII: the economy's impact on CSII's price and risk, featuring the powerful EconomicInvestor Star Rating6$15View Abstract
25-Jan-10Wall Street Transcript ,TheThe Wall St TranscriptANALYST INTERVIEW: Blurred Lines Between Life Sciences & Diagnostics - Stephen D. Simpson - Northland Securities, Inc.5$50View Abstract
25-Jan-10Wall Street Transcript ,TheThe Wall St TranscriptWall Street Transcript Special Report: Medical Research, Diagnostic Substances, Life Science Tools Report35$150View Abstract
19-Jan-10Zacks Investment Research Inc.N/ACARDIOVASCLR SY (CSII) Zacks Company Snapshot1$10View Abstract
4-Jan-10Zacks Investment Research Inc.N/ACARDIOVASCLR SY (CSII) Zacks Company Snapshot1$10View Abstract
30-Dec-09Zacks Investment Research Inc.N/ACARDIOVASCLR SY (CSII) Zacks Company Snapshot1$10View Abstract
Next 2

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.